# Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

> **NCT04285671** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Lung Non-Small Cell Carcinoma
- Refractory Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Necitumumab
- **DRUG:** Osimertinib
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT04285671
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-29
- **Primary completion:** 2026-12-02
- **Final completion:** 2027-12-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04285671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04285671, "Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04285671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*